公开(公告)号：US20230303538A1

公开(公告)日：2023-09-28

申请号：US17927426

申请日：2021-05-27

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： CHUNJIAN LIU ,  Wei Wang ,  Bruce A. Ellsworth ,  James Aaron Balog ,  Alicia Regueiro-Ren

IPC: C07D405/14

CPC classification number: C07D405/14

Abstract: The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

公开(公告)号：US20240317718A1

公开(公告)日：2024-09-26

申请号：US18560485

申请日：2022-05-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： STEVEN H. SPERGEL ,  RYAN M. MOSLIN ,  MICHAEL EDWARD MERTZMAN ,  SHOSHANA L. POSY ,  SIRISH KAUSHIK LAKKARAJU ,  JOSEPH A. TINO ,  ZILI XIAO ,  CHUNJIAN LIU ,  JAMES LIN

IPC: C07D403/12 ,  A61K31/501 ,  A61K31/506 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14

CPC classification number: C07D403/12 ,  A61K31/501 ,  A61K31/506 ,  C07D401/12 ,  C07D401/14 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14

Abstract: There are disclosed compounds of the following formula (I) or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.

公开(公告)号：US20240002364A1

公开(公告)日：2024-01-04

申请号：US18461093

申请日：2023-09-05

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： CHUNJIAN LIU ,  MICHAEL G. YANG ,  ZILI XIAO ,  LING CHEN ,  RYAN M. MOSLIN ,  JOHN S. TOKARSKI ,  DAVID S. WEINSTEIN ,  STEPHEN T. WROBLESKI

IPC: C07D401/14 ,  C07D401/12 ,  C07D413/14 ,  C07D471/04 ,  C07D405/14 ,  C07F9/6558 ,  C07D417/14 ,  A61P37/00 ,  A61P29/00 ,  A61K31/501 ,  C07D487/04

CPC classification number: C07D401/14 ,  C07D401/12 ,  C07D413/14 ,  C07D471/04 ,  C07D405/14 ,  C07F9/65583 ,  C07D417/14 ,  A61P37/00 ,  A61P29/00 ,  A61K31/501 ,  C07D487/04

Abstract: Compounds having the following formula I:




or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.